The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).

[1]  J. Bertino,et al.  Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Michaelis,et al.  Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Fleming,et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Wieand,et al.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Collier,et al.  A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. M. Hamilton.  Multiple confirmatory trials. How can additional studies be of value? , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Michael R. Green,et al.  The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial , 1990 .

[11]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Hannigan,et al.  Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Cavalli,et al.  A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. , 1988, European journal of cancer & clinical oncology.

[14]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .